BHVN Biohaven Ltd

Price (delayed)

$11.2

Market cap

$1.69B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.58

Enterprise value

$1.69B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 8

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Highlights
BHVN's quick ratio has surged by 143% since the previous quarter
The EPS rose by 40% year-on-year and by 19% since the previous quarter
The equity has surged by 149% since the previous quarter but it has dropped by 50% year-on-year

Key stats

What are the main financial stats of BHVN

BHVN stock price

How has the Biohaven stock price performed over time
Intraday
3.61%
1 week
9.38%
1 month
10.45%
1 year
-30.91%
YTD
-0.8%
QTD
32.39%

Financial performance

How have Biohaven's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$654.25M
Net income
-$647.68M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 29% YoY and by 12% QoQ
Biohaven's net income has increased by 27% YoY and by 12% from the previous quarter

Price vs fundamentals

How does BHVN's price correlate with its fundamentals

Growth

What is Biohaven's growth rate over time

Valuation

What is Biohaven stock price valuation
P/E
N/A
P/B
13.01
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 40% year-on-year and by 19% since the previous quarter
The equity has surged by 149% since the previous quarter but it has dropped by 50% year-on-year

Efficiency

How efficient is Biohaven business performance
Biohaven's return on invested capital has surged by 55% YoY and by 22% QoQ
The ROE has decreased by 26% from the previous quarter
The ROA has grown by 16% YoY and by 13% from the previous quarter

Dividends

What is BHVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BHVN.

Financial health

How did Biohaven financials performed over time
The company's total assets is 38% higher than its total liabilities
BHVN's quick ratio has surged by 143% since the previous quarter
The current ratio has surged by 133% since the previous quarter
The company's debt is 116% higher than its equity
The equity has surged by 149% since the previous quarter but it has dropped by 50% year-on-year
BHVN's debt to equity has dropped by 60% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.